25,729 articles
Rigor mortis
Rigor mortis (dødsstivhet), postmortem muscular stiffening from ATP depletion and persistent actin-myosin binding; begins 1-2 hours after death, follows Nysten's rule, resolves in 24-48 hours.
Rigosertib
Rigosertib (ON 01910.Na) is an investigational non-ATP-competitive anticancer drug, a benzyl styryl sulfone sodium salt targeting Plk1, PI3K, and Ras signaling; phase 3 MDS trials (ONTIME) showed no significant survival benefit.
Rigshospitalet
Rigshospitalet, Copenhagen University Hospital, Denmark's most specialized hospital, founded 1757 as Det Kongelige Frederiks Hospital by Frederik V, moved to Blegdamsvej in 1910, national referral hospital for Denmark, Greenland, and the Faroe Islands.
Rilematovir
Rilematovir (JNJ-53718678) was Janssen's oral small-molecule RSV fusion (F) protein inhibitor of the indole class; proof of concept in a challenge study, but development was discontinued in April 2022 after weak efficacy in natural infection.
Rilimogene galvacirepvec
Rilimogene galvacirepvec (PROSTVAC-V, V-PSA-TRICOM) is a recombinant vaccinia virus prime of the PROSTVAC prostate cancer vaccine, paired with fowlpox booster rilimogene glafolivec; phase III PROSPECT showed no survival benefit.
Riliprubart
Riliprubart (SAR445088, BIVV020, TNT020) is Sanofi's investigational humanized IgG4 monoclonal antibody inhibiting activated C1s in the classical complement pathway, studied in cold agglutinin disease and CIDP; its MOBILIZE phase 3 CIDP trial was stopped for futility in June 2026.
Rilmenidine
Rilmenidine (Hyperium) is an imidazoline I1-receptor agonist antihypertensive, 1–2 mg once daily, not available in the US; effective in mild-to-moderate hypertension with less sedation and no rebound than clonidine.
Rilonacept
Rilonacept (ARCALYST) is a subcutaneous IL-1α/IL-1β cytokine trap approved for CAPS, DIRA remission maintenance, and recurrent pericarditis; dosed 320 mg loading then 160 mg weekly, with injection-site reactions and upper respiratory infections as common adverse effects.
Rilotumumab
Rilotumumab (AMG 102) is Amgen's fully human monoclonal antibody neutralizing HGF to block MET signaling. Its phase 3 RILOMET-1 gastric cancer trial showed harm, and Amgen terminated all studies in November 2014.
Rilpivirine
Rilpivirine (RPV, TMC278), a diarylpyrimidine NNRTI for HIV-1, dosed 25 mg once daily with food; non-inferior to efavirenz in ECHO/THRIVE; also long-acting injectable with cabotegravir (Cabenuva).
Riluzole
Riluzole (Rilutek, Tiglutik, Exservan) is an antiglutamatergic drug for ALS, FDA-approved in 1995; it prolongs median survival by two to three months and remains the only globally approved disease-modifying ALS therapy.
Rilvegostomig
Rilvegostomig (AZD2936) is AstraZeneca's investigational monovalent bispecific humanized IgG1 antibody targeting PD-1 and TIGIT, with a reduced-Fc triple mutation and a TIGIT arm from Compugen's COM902, in Phase 3 NSCLC and other solid tumor trials.
Rilzabrutinib
Rilzabrutinib (Wayrilz, PRN1008), an oral reversible covalent Bruton's tyrosine kinase inhibitor by Sanofi, approved 2025-2026 in the US, EU, and UK for refractory adult immune thrombocytopenia.
Rimantadine
Rimantadine (Flumadine, rimantadine hydrochloride) is an adamantane antiviral that blocks the M2 ion channel of influenza A only; FDA approved 1993, abandoned after widespread S31N resistance.
Rimegepant
Rimegepant (Nurtec ODT, Vydura) is an oral CGRP receptor antagonist (gepant) approved in 2020 for acute migraine treatment in adults and later for episodic migraine prevention, dosed 75 mg orally or every other day.
Rimexolone
Rimexolone (Vexol, Org 6216) is a 1% ophthalmic glucocorticoid suspension for postoperative ocular inflammation and anterior uveitis, with lower IOP-elevating potential than prednisolone; US product discontinued.
RIN2 syndrome
RIN2 syndrome, also known as MACS syndrome, is an extremely rare autosomal recessive connective tissue disorder, first described in 2009, marked by macrocephaly, sparse hair, lax skin, and scoliosis.
Rinatabart sesutecan
Rinatabart sesutecan (Rina-S, PRO1184, GEN1184) is an investigational FRα-targeted antibody-drug conjugate with an exatecan topoisomerase I inhibitor payload and hydrophilic linker, developed by ProfoundBio, acquired by Genmab, in phase 3 trials for ovarian and endometrial cancer.
Ring annuloplasty
Ring annuloplasty is a valve repair operation in which a prosthetic ring is sutured around the mitral or tricuspid valve annulus to restore its normal size and shape.
Ring chromosome 1 syndrome
Ring chromosome 1 syndrome (r(1) syndrome, Ring 1) is an ultra-rare autosomal chromosomal anomaly, under 1 per million, causing growth failure, microcephaly, developmental delay, intellectual disability, and possible malignancy predisposition.
Ring chromosome 10 syndrome
Ring chromosome 10 syndrome (r(10)) is an extremely rare chromosomal disorder from de novo breakage and fusion of chromosome 10, causing deletions; about 20 reported cases show ID/DD, microcephaly, growth retardation, strabismus, and genitourinary malformations.
Ring chromosome 11 syndrome
Ring chromosome 11 syndrome (r(11) syndrome) is a rare chromosomal disorder in which chromosome 11 forms a ring, causing short stature, microcephaly, and intellectual disability.
Ring chromosome 12 syndrome
Ring chromosome 12 syndrome (Ring 12, ORPHA:1439) is an ultra-rare chromosomal disorder, about ten reported cases, caused by a ring chromosome 12 with terminal deletions, causing growth retardation, developmental delay, microcephaly, and facial dysmorphism.
Ring chromosome 13 syndrome
Ring chromosome 13 syndrome (ring 13, r(13)) is a rare chromosomal anomaly, about 1 in 58,000 live births, in which chromosome 13 ends fuse into a ring with terminal gene loss, causing variable growth retardation, intellectual disability, microcephaly, and dysmorphism, usually sporadic and mosaic.
Ring chromosome 15 syndrome
Ring chromosome 15 syndrome (ring 15, r(15)) is a rare chromosomal disorder from deletion of 15q and ring formation, causing growth retardation, short stature, intellectual disability, dysmorphism, and skin pigment spots; prevalence under 1 in 1,000,000.
Ring chromosome 16 syndrome
Ring chromosome 16 syndrome (Ring 16, r(16)) is an ultra-rare chromosomal disorder with fewer than 10 reported cases, caused by a ring-shaped chromosome 16, featuring growth and developmental delay, intellectual disability, microcephaly, and craniofacial dysmorphism.
Ring chromosome 17 syndrome
Ring chromosome 17 syndrome (Ring 17, ORPHA:1441) is an ultra-rare chromosomal anomaly, under 1 in 1,000,000, where chromosome 17 forms a circle; severity depends on whether the Miller-Dieker critical region on 17p13.3 is deleted.
Ring chromosome 18 syndrome
Ring chromosome 18 syndrome (Ring 18) is a rare chromosomal disorder where chromosome 18's ends fuse into a ring, deleting genetic material from one or both arms; features overlap 18p- and distal 18q- syndromes, occurring in about 1 in 300,000 births.
Ring chromosome 19 syndrome
Ring chromosome 19 syndrome (Ring 19, ORPHA:1443) is a rare chromosomal anomaly, under 1 in 1,000,000, with variable phenotype from normal to profound intellectual disability, developmental delay, dysmorphism, and autistic-like mannerisms.
Ring chromosome 2 syndrome
Ring chromosome 2 syndrome (ring 2, ORPHA:96171) is an extremely rare chromosomal disorder where chromosome 2's ends fuse into a ring, causing growth retardation, microcephaly, hypotonia, and developmental delay; fewer than 1 in 1,000,000, usually sporadic.